JP2020503883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503883A5 JP2020503883A5 JP2019538347A JP2019538347A JP2020503883A5 JP 2020503883 A5 JP2020503883 A5 JP 2020503883A5 JP 2019538347 A JP2019538347 A JP 2019538347A JP 2019538347 A JP2019538347 A JP 2019538347A JP 2020503883 A5 JP2020503883 A5 JP 2020503883A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- nos
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 56
- 108091008874 T cell receptors Proteins 0.000 claims 46
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 46
- 210000004027 cell Anatomy 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical group 0.000 claims 14
- 239000013598 vector Substances 0.000 claims 14
- 238000003776 cleavage reaction Methods 0.000 claims 12
- 230000007017 scission Effects 0.000 claims 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 102000004961 Furin Human genes 0.000 claims 4
- 108090001126 Furin Proteins 0.000 claims 4
- 102000011786 HLA-A Antigens Human genes 0.000 claims 4
- 108010075704 HLA-A Antigens Proteins 0.000 claims 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000006337 proteolytic cleavage Effects 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 3
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 210000004877 mucosa Anatomy 0.000 claims 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101100451497 Dictyostelium discoideum hspB gene Proteins 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 101150022862 HSC70 gene Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950006370 epacadostat Drugs 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 244000144980 herd Species 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023000639A JP2023029503A (ja) | 2017-01-13 | 2023-01-05 | Ｎｙ－ｅｓｏ－１に結合するｔ細胞受容体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446084P | 2017-01-13 | 2017-01-13 | |
| US62/446,084 | 2017-01-13 | ||
| PCT/US2018/013624 WO2018132739A2 (en) | 2017-01-13 | 2018-01-12 | T cell receptors that bind to ny-eso-1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000639A Division JP2023029503A (ja) | 2017-01-13 | 2023-01-05 | Ｎｙ－ｅｓｏ－１に結合するｔ細胞受容体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020503883A JP2020503883A (ja) | 2020-02-06 |
| JP2020503883A5 true JP2020503883A5 (https=) | 2021-02-25 |
Family
ID=61656335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538347A Ceased JP2020503883A (ja) | 2017-01-13 | 2018-01-12 | Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法 |
| JP2023000639A Pending JP2023029503A (ja) | 2017-01-13 | 2023-01-05 | Ｎｙ－ｅｓｏ－１に結合するｔ細胞受容体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000639A Pending JP2023029503A (ja) | 2017-01-13 | 2023-01-05 | Ｎｙ－ｅｓｏ－１に結合するｔ細胞受容体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11613764B2 (https=) |
| EP (1) | EP3568412A2 (https=) |
| JP (2) | JP2020503883A (https=) |
| KR (1) | KR20190103226A (https=) |
| CN (1) | CN110198954A (https=) |
| AU (1) | AU2018207172B2 (https=) |
| BR (1) | BR112019014510A2 (https=) |
| CA (1) | CA3049016A1 (https=) |
| EA (1) | EA201991696A1 (https=) |
| IL (1) | IL267878A (https=) |
| MA (1) | MA47265A (https=) |
| MX (1) | MX2019008346A (https=) |
| WO (1) | WO2018132739A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102543325B1 (ko) | 2018-08-13 | 2023-06-13 | 루트패스 제노믹스, 인크. | 쌍을 이룬 이분 면역수용체 폴리뉴클레오티드의 고처리량 클로닝 및 이의 적용 |
| CA3111381A1 (en) * | 2018-09-05 | 2020-04-30 | The Regents Of The University Of California | Composition of ny-eso-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules |
| KR102933479B1 (ko) * | 2018-10-23 | 2026-03-04 | 리제너론 파아마슈티컬스, 인크. | Ny-eso-1 t 세포 수용체 및 이의 사용 방법 |
| SG11202110956RA (en) * | 2019-04-05 | 2021-10-28 | Rootpath Genomics Inc | Compositions and methods for t-cell receptor gene assembly |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| MA56468A (fr) | 2019-07-03 | 2022-05-11 | Regeneron Pharma | Protéines de liaison à l'antigène de carcinome 1 à cellules squameuses de l'oesophage anti-new york (ny-eso-1) et leurs procédés d'utilisation |
| CN114616467B (zh) * | 2019-10-03 | 2026-04-07 | 瑞泽恩制药公司 | 筛选原代人类细胞中的同源t细胞和表位反应性的高通量方法 |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240366741A1 (en) * | 2021-03-12 | 2024-11-07 | Purdue Research Foundation | Novel vaccine formulations for mycobacterium tuberculosis and use of thereof |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| WO2023077028A1 (en) * | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Enhanced t cell therapy targeting ny-eso-1 |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121443326A (zh) * | 2023-06-30 | 2026-01-30 | 森迪生物科学公司 | 改进的多顺反子系统及其用途 |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| US6645495B1 (en) | 1997-08-29 | 2003-11-11 | Antigenics, Inc. | Compositions of saponin adjuvants and excipients |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| US7049302B1 (en) | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| US6194137B1 (en) | 1999-04-13 | 2001-02-27 | Organ Recovery Systems, Inc. | Method of cryopreservation of blood vessels by vitrification |
| US7052906B1 (en) | 1999-04-16 | 2006-05-30 | Celltech R & D Limited | Synthetic transmembrane components |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| WO2004078776A2 (en) | 2003-03-04 | 2004-09-16 | Ludwig Institute For Cancer Research | Ny-eso-1 peptides which bind to class ii molecules and uses thereof |
| DK1765860T3 (da) * | 2004-05-19 | 2009-03-09 | Immunocore Ltd | Ny-ESO-T.cellereceptor med höj affinitet |
| US8361794B2 (en) | 2004-06-29 | 2013-01-29 | Immunocore Limited | Cells expressing a modified T cell receptor |
| US7915036B2 (en) | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| GB0712670D0 (en) | 2007-06-29 | 2007-08-08 | King S College London | Isolated peptides and uses thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2408819A2 (en) | 2009-03-20 | 2012-01-25 | Ludwig Institute for Cancer Research Ltd | High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| US8920075B2 (en) | 2011-09-01 | 2014-12-30 | Halo Maritime Defense Systems, Inc. | Marine barrier and gate |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| JP6378172B2 (ja) * | 2012-05-22 | 2018-08-22 | アメリカ合衆国 | マウス抗ｎｙ−ｅｓｏ−１ｔ細胞受容体 |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| AU2013295652B2 (en) * | 2012-07-27 | 2018-02-08 | The Board Of Trustees Of The University Of Illinois | Engineering T-cell receptors |
| JP6403166B2 (ja) | 2012-08-03 | 2018-10-10 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法 |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014160030A2 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| US10077305B2 (en) | 2013-09-10 | 2018-09-18 | Medimmune Limited | Antibodies against PD-1 and uses thereof |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| WO2015061668A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| CN104558177B (zh) | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| SI3094351T1 (sl) | 2014-01-15 | 2022-05-31 | Kadmon Corporation, Llc | Imunomodulatorna sredstva |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| EP3149042B1 (en) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| WO2016020856A2 (en) | 2014-08-05 | 2016-02-11 | MabQuest SA | Immunological reagents |
| MY193723A (en) | 2014-08-29 | 2022-10-27 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
-
2018
- 2018-01-12 CN CN201880006628.9A patent/CN110198954A/zh active Pending
- 2018-01-12 AU AU2018207172A patent/AU2018207172B2/en not_active Ceased
- 2018-01-12 EA EA201991696A patent/EA201991696A1/ru unknown
- 2018-01-12 JP JP2019538347A patent/JP2020503883A/ja not_active Ceased
- 2018-01-12 WO PCT/US2018/013624 patent/WO2018132739A2/en not_active Ceased
- 2018-01-12 MX MX2019008346A patent/MX2019008346A/es unknown
- 2018-01-12 EP EP18711429.3A patent/EP3568412A2/en active Pending
- 2018-01-12 BR BR112019014510-9A patent/BR112019014510A2/pt not_active IP Right Cessation
- 2018-01-12 MA MA047265A patent/MA47265A/fr unknown
- 2018-01-12 KR KR1020197021319A patent/KR20190103226A/ko not_active Ceased
- 2018-01-12 CA CA3049016A patent/CA3049016A1/en active Pending
-
2019
- 2019-07-07 IL IL267878A patent/IL267878A/en unknown
- 2019-07-15 US US16/512,031 patent/US11613764B2/en active Active
-
2023
- 2023-01-05 JP JP2023000639A patent/JP2023029503A/ja active Pending
- 2023-03-27 US US18/190,954 patent/US20240102044A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503883A5 (https=) | ||
| JP7744479B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 | |
| US20230190796A1 (en) | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods | |
| JP6639233B2 (ja) | Ｍａｇｅ−ａ１を認識する高結合活性結合分子 | |
| JP2022050400A (ja) | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 | |
| JP2020532304A5 (https=) | ||
| CA2959318A1 (en) | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations | |
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| US20220249637A1 (en) | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein | |
| AU2014225788A1 (en) | Engager cells for immunotherapy | |
| RS58448B1 (sr) | Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba | |
| KR20220066090A (ko) | 마우스 및 인간 섬유아세포 활성화 단백질(fap)과 교차 반응하는 개과 섬유아세포 활성화 단백질에 대한 모노클로날 항체 | |
| IL309003A (en) | Novel peptides, combination of peptides and scaffolds for use in immunothera-peutic treatment of various cancers | |
| US11951131B2 (en) | Anti-SLAMF7 chimeric antigen receptors | |
| CN115768464A (zh) | 产生工程化记忆样nk细胞及其组合物的方法 | |
| JP2024505428A (ja) | Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ | |
| JP2024144409A (ja) | がん幹細胞特異的抗体 | |
| EP1413316A1 (en) | Bifunctional conjugates or fusion proteins | |
| JP2022542443A (ja) | 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞 | |
| US20240181052A1 (en) | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy | |
| WO2003104429B1 (en) | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics | |
| TWI805792B (zh) | 抗腫瘤劑及其評估方法 | |
| US12209137B2 (en) | Antigen binding proteins specifically binding CT45 | |
| US20240148867A1 (en) | Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine | |
| Flanagan et al. | H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models |